Skip to main content

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives


Chronic inflammation and involvement of myeloid blood cells are associated with the development of Alzheimer’s disease (AD). Chronic inflammation is a highly important driving force for the development and progression of the chronic myeloproliferative blood cancers (MPNs), which are characterized by repeated thrombotic episodes years before MPN-diagnosis, being elicited by elevated erythrocytes, leukocytes, and platelets. Mutations in blood cells, the JAK2V617F and TET2-mutations, contribute to the inflammatory and thrombogenic state. Herein, we discuss the MPNs as a human neuroinflammation model for AD development, taking into account the many shared cellular mechanisms for reduction in cerebral blood, including capillary stalling with plugging of blood cells in the cerebral microcirculation. The therapeutic consequences of an association between MPNs and AD are immense, including reduction in elevated cell counts by interferon-alpha2 or hydroxyurea and targeting the chronic inflammatory state by JAK1-2 inhibitors, e.g., ruxolitinib, in the future treatment of AD.


The Philadelphia-negative myeloproliferative neoplasms (MPNs)

The Philadelphia-negative myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) are chronic blood cancers [1] with a long pre-diagnostic phase, spanning up to 15–20 years [2]. In recent years, evidence has accumulated that chronic inflammation is a highly important driving force for the development and progression of MPNs [3,4,5,6,7]. Similar to patients with type II diabetes mellitus (DM), most patients with MPNs experience several thrombotic episodes years before MPN-diagnosis [2, 4], being elicited by elevated activated leukocytes and platelets and an activated dysfunctional endothelium as well [8]. Thus, both the metabolic syndrome and type II DM share several features with MPNs, the ultimate outcome being premature atherosclerosis development with organ dysfunction, and organ failure such as cognitive impairment, memory loss and dementia development, age-related macular degeneration, heart failure, peripheral vascular insufficiency, and chronic nephropathy [3,4,5, 9].

Taking into account the tight association between chronic inflammation and common comorbidities/multimorbidities in the general population [10] and the MPNs as “A Human Inflammation Model” [3,4,5,6,7], we believe that the MPNs are unique model diseases to elucidate common mechanisms for disease development, including the association between, e.g., MPNs and Alzheimer’s disease (AD), thereby opening an avenue for exploring new treatment targets that may benefit patients with a heavy burden of comorbidities such as patients with AD and the MPNs.

Herein, we argue for neuroinflammation and neurodegeneration being integrated in the CNS-related symptom burden in patients with MPNs. Based upon epidemiological, clinical, molecular, immunological, and genomic studies, we discuss the similarities between a common, classic neuroinflammatory disease—AD—and the myeloproliferative blood cancers, the MPNs. It is hypothesized that AD may be prevalent in MPNs but undiagnosed since the debilitating CNS symptoms are overlooked and misinterpreted as being part of the complex burden of CNS-symptoms consequent to multiple infarctions and impaired cerebral microcirculation in patients with MPNs. Since MPNs are seemingly not orphan diseases but actually prevalent underdiagnosed chronic blood cancers [11] with a long pre-MPN-phase of several years (5-10-20 years) [2]—very similar to AD—studies are urgently needed to explore associations between these two chronic inflammatory diseases. The rationales for such studies will be given below with a discussion of common pathways aimed to improve quality of life and prognosis of patients with these diseases, including not least earlier diagnosis to improve clinical outcomes by earlier therapeutic intervention [3, 4, 9, 12,13,14,15]. Such efforts are even more urgent, since no current medical therapies are able to revert the advanced stages of AD and MPNs, characterized by severe dementia and severe bone marrow fibrosis, respectively.

The MPNs as model diseases for the link between chronic inflammation, neuroinflammation, and Alzheimer’s disease

The concept

Chronic inflammation is the common link between highly prevalent diseases such as atherosclerosis, the metabolic syndrome, type II DM and cancer, in which the JAK-STAT-signaling and the NF-kB pathways are activated and play a major role in disease progression [10, 16,17,18,19,20,21,22]. These pathways are constitutively activated in MPNs due to driver mutations, e.g., the JAK2V617F mutation, giving rise to sustained elevation of blood cell counts, which in PV always include elevated hematocrit but often leukocytosis and thrombocytosis as well, in ET always elevated platelet counts and in MF in the early hyperproliferative phase leukocytosis and thrombocytosis and in the advanced stages of MF often pancytopenia [1]. Importantly, circulating leukocytes and platelets are in vivo activated with a marked propensity to adhere to each other (circulating microaggregates giving rise to decreased blood flow in the microcirculation in the brain, retina, heart, lungs, and elsewhere) and to adhere to dysfunctional endothelium [8, 23]. Chronic inflammation is also involved in the huge inflammation-mediated MPN-disease burden [3,4,5,6,7] with a massive CNS-related symptom burden, significantly impairing quality of life [24] and also impacting patients’ overall health and productivity [25]. The CNS symptom burden has been attributed to compromised cerebral microcirculation due to elevated cell counts and activated circulating myeloid cells and microaggregates of leukocytes and platelets [1, 8] which intermittently may plug the cerebral microcirculation as described above.

Based upon the above considerations, we herein use the MPNs as “A Human Inflammation Model” [3,4,5,6,7] and as “A Human Model for a Link Between Myeloid Proliferation and Neuroinflammation” to explore and increase our understanding of causative mechanisms of neurodegeneration—not only in MPNs—but in other chronic inflammatory diseases, which are frequently associated with variably elevated blood cell counts, including the metabolic syndrome, type II DM, cardiovascular disease, chronic obstructive pulmonary disease, inflammatory bowel diseases (IBD), and rheumatic diseases such as polymyalgia rheumatica. Table 1 summarizes similarities between common inflammatory diseases, MPNs, and AD.

Table 1 Similarities between MPNs, Alzheimer’s disease, type II DM, chronic inflammatory diseases, and smoking

Links between Alzheimer’s disease and MPNs. Alzheimer’s disease—a myeloid blood cell disorder?

Major hallmarks of Alzheimer’s disease include vascular dysfunction and cerebral hypoperfusion, degeneration of neurons, and synapses with the development of senile plaques and neurofibrillary tangles in the brain [26, 27]. Senile plaques are characterized by the abnormal accumulation of amyloid β-peptide (Aβ), derived from the metabolism of the larger amyloid precursor protein, APP, abundantly expressed in platelets which process APP through the same pathways as in the brain. Accordingly, platelets have been used as a model to study pathophysiological aspects for development of AD [28].

A role of platelets in the pathogenesis of Alzheimer’s disease?

Platelets are activated in patients with MPNs and in patients with Alzheimer’s disease

Being highly important immunoinflammatory cells, platelets secrete an array of the most potent inflammatory signaling molecules, including chemokines (platelet factor 4, PF4, RANTES, and MIP-1α), interleukins (IL-1β, IL-7, and IL-8), prostaglandins, and CD40L [29].

Upon activation by various platelet agonists, platelets also release a vast amount of Aβ peptides and among these in particular Aβ1-40, which mainly contributes to vascular amyloid deposits, whereas the predominant form in neuronal plaques is Aβ1-42 [28].

The prevailing hypothesis on AD pathogenesis—the Aβ hypothesis—is that brain cells are responsible for Aβ peptide overproduction [30, 31]. An alternative hypothesis has recently been developed, implying that beta amyloidosis is developed from Aβ peptides that spread to the brain from the blood. In this context, platelets are indeed candidates to be involved in AD pathogenesis for several reasons. First, as alluded to above, platelets have relatively high concentrations of APP, being released from platelets upon platelet activation [32]. Second, platelets are also the primary source of Aβ peptide in human blood ( 90%) [33]. Importantly, this Aβ peptide is similar to that found in the senile plaques of AD patients—and is similarly increased in patients with familial AD harboring APP mutations [34]. Third, the activated platelets in AD have been shown to retain greater amounts of APP [35] and more platelet adhesion and thrombus formation [36]. Fourth, after experimental thrombosis, Aβ peptide has been detected by immunocytochemistry in and around the blood vessels in the brain, and this peptide is released from platelets [37]. Fifth, an association between microinfarcts and AD pathology has been known for several years [38].

The above mentioned platelet proteins also participate in the transendothelial migration of leukocytes when Aβ peptide promotes an inflammatory stimulus. Thus, the uncontrolled activation of platelets in AD patients ultimately results in a chronic inflammatory reaction in brain vessels, implying a sustained endothelial cell stress, which, in turn, may trigger further platelet activation, thereby creating a self-perpetuating vicious circle with further increase in inflammation load and release of Aβ [39, 40]

Elevated platelet counts are one of the hallmarks in most patients with MPNs—at least in the early MPN cancer stages. Due to the driver mutations—JAK2V617F, CALR, and MPL—circulating leukocytes and platelets are also hyperactivated which together with an activated and dysfunctional endothelium elicit a highly thrombogenic condition, which contributes significantly to the huge cardiovascular disease burden. Since platelet activation with release of platelet granule contents, including Aβ and inflammatory cytokines, is considered of paramount importance for AD development [39, 40], it is intriguing to consider that circulating hyperactive platelets in MPN patients—being excessive both in the systemic circulation and in the microcirculation in the brain—might liberate a vast amount of Aβ and inflammatory cytokines in the brain as well. An association between MPNs and development of AD due to an excessive and sustained release of Aβ from circulating activated platelets [39, 40] might deliver additional fuel to the theory that neuroinflammation in AD is elicited and evolves consequent to a chronic systemic inflammatory state [39, 40] which also drives MPN—disease progression in the biological continuum from the early MPN—cancer stages (ET and PV) towards the advanced myelofibrosis stage with bone marrow failure [3,4,5,6,7] and in many patients a huge inflammation-mediated comorbidity burden [3, 4] (Figs. 1, 2, 3, and 4).

Fig. 1

The myeloproliferative blood cancers—essential thrombocytosis (ET), polycythemia vera (PV), and myelofibrosis (MF)—(MPNs) evolve in a biological continuum, spanning 5-10-20 years from the early cancer stages (ET/PV) towards the advanced MF stage. Chronic inflammation is the driving force for this development giving rise to increasing oxidative stress and increasing genomic instability. Inflammatory cytokines drive clonal evolution, and the clone itself generates oxidative stress and inflammatory products which in a self-perpetuating vicious circle elicits more fuel to the fire. In the initial stages of MPNs (ET, PV, and hyperproliferative MF), blood cell counts are elevated (in PV always red blood cells but very often leukocytes and platelets as well, in ET always elevated platelet counts and in some patients elevated leukocyte counts as well and in MF elevated leukocyte and platelet counts). Neuroinflammation is associated with several chronic inflammatory diseases. It is argued that chronic systemic inflammation in MPNs may also elicit neuroinflammation in MPNs and contribute to the CNS-symptom burden in patients with MPNs. It is hypothesized that MPNs are “A Human Neuroinflammation Model” for Alzheimer’s disease development

Fig. 2

Impact of early intervention with interferon-alpha2 (IFN) + JAK1/2 inhibitor ± statin upon the vicious self-perpetuating circle in MPNs. Early intervention with combination therapy is foreseen to prohibit disease progression by directly targeting the malignant clone (interferon) in concert with dampening of the inflammatory state (JAK1/2 inhibition, statin), which drives the malignant clone and also creates the soil for neuroinflammation and later development of Alzheimer’s disease. From this model, it is envisaged that treatment with IFN and JAK1/2 inhibitor may also be a highly important combination therapy for patients with early stage Alzheimer’s disease

Fig. 3

The myeloproliferative blood cancers, MPNs, are associated with chronic inflammation and oxidative stress, which drive the malignant clone from the early cancer stages—ET and PV—towards the advanced burnt-out myelofibrosis stage with bone marrow failure. Smoking is a known risk factor for both MPN- and Alzheimer’s disease (AD) development. By triggering the NF-kB and JAK-STAT pathways, smoking elicits the production of several proinflammatory cytokines, including IL-6, IL-8, and TNF-alpha, which are released from leukocytes and platelets and also give rise to leukocyte-, platelet, and endothelial cell activation. A huge amount of amyloid beta is released from circulating activated platelets. Taking into account that the above pathways are activated in MPNs and AD as well, and the MPNs and AD share a similar inflammatory landscape, it is intriguing to consider, if leukocyte and platelet activation together with chronic inflammation and oxidative stress may constitute the common links, which are determinant for eliciting neuroinflammation, capillary stalling due to plugging of the microcirculation with activated blood cells and ultimately decreased cerebral blood flow and AD development

Fig. 4

Mutations in blood cells give rise to chronic inflammation and elevated leukocyte and platelet counts, which together with endothelial cells are hyperactivated in MPNs. In polycythemia vera, red blood cell counts are elevated as well. Patients with MPNs and Alzheimer’s disease share several common pathways, which all together unite the different hypotheses of AD, the common denominators being chronic neuroinflammation and cerebral hypoperfusion, the latter being elicited by capillary stalling due to plugging of myeloid cells in the cerebral microcirculation

A role of white blood cells in the pathogenesis of Alzheimer’s disease?

White blood cells—neutrophils and monocytes—are activated in patients with MPNs

Leukocytosis is common in patients with MPNs and associates with an increased risk of thrombosis [1, 8], being explained by several mechanisms, including in vivo activation with aggregation to each other, activated platelets and monocytes, thereby giving rise to circulating microaggregates of activated myeloid cells with ensuing impairment of blood flow in the microcirculation in vital organs, such as the brain, heart, and lungs. A decrease of cerebral blood induces hypoxemia and activation of several signaling pathways which ultimately elicit a neuroinflammatory state with microglia activation and induction of inflammatory cytokines of importance for development of AD (e.g., IL-1beta, IL-6, IL-8, TNF-alpha). Taking into account that persistent leukocytosis with in vivo granulocyte and monocytic activation has preceded the diagnosis of MPNs for several years (5-10-20 years) and leukocytosis in several patients (low risk without prior thrombosis, platelet count < 1500 × 109/L, < 60 years) is not treated, it is intriguing to consider if these chronic blood cancers may predispose to development of neuroinflammatory diseases, such as AD, in which myeloid cells are being increasingly considered of major importance in disease development (Figs. 1, 2, 3, and 4).

Although the significance of leukocytes in the pathogenesis of AD has been addressed in several studies, the literature on circulating cell counts in AD patients is sparse and conflicting; some reporting normal cell counts except for moderate anemia and others elevated neutrophil and monocyte counts [41]. In addition to the above mechanisms, neutrophil extracellular trap (NET) formation may be another highly important thrombogenic factor, both in MPNs, in which the JAK2V617F mutation induces NETosis but also in patients with AD [42]. Importantly, in mice, leukocytes have been shown to plug the cerebral microcirculation both in MPN mouse models [43] and in models of AD [44], which will be addressed in detail below. Furthermore, it might be worth speculating if AD with deposition of Aβ in CNS might be explained by defective clearance of excessive Aβ deposition in the CNS due to defective monocytes and defective other immune cells as well [45].

Do elevated red blood cells (RBCs) in patients with polycythemia vera contribute to development of Alzheimer’s disease?

Elevated RBC counts are associated with an increased risk of arterial thrombosis both in the background population and in patients with MPNs [1]. Red blood cells from patients with PV have been shown to adhere more strongly to endothelial cells. This propensity is mediated by the JAK2V617F mutation and may be an additional thrombogenic factor in PV patients but also in the context of PV as a disease, which may predispose to the development of AD.

An impact of RBCs in the pathophysiology of AD is supported by several observations. First, an elevated hematocrit is associated with decreased cerebral blood flow and accordingly cerebral hypoxemia [46]. Second, Aβ binds with high affinity to RBCs and induces oxidative damage to RBCs, which may contribute to the pathogenesis of AD [47]. Third, oxygen delivery to tissues requires that RBCs must be deformable to pass through the microcirculation. When exposed to amyloid beta fibrils, RBCs exhibit decreased deformality. Accordingly, Aβ interactions with RBCs in AD patients may result in impaired oxygen transport and delivery [48].

Shared cellular mechanisms for reduction in cerebral blood in patients with MPNs and in patients with Alzheimer’s disease?

The MPNs have been named “vascular diseases” due to the sustained prothrombogenic state in the inflamed and activated vascular bed, which also involves the cerebral microcirculation. In PV, the increased number of RBCs contributes significantly to high blood viscosity in the cerebral microcirculation with increased vascular resistance and slowing of blood flow [23, 46]. Similarly, both leukocytosis and thrombocytosis per se may increase resistance in blood vessels and accordingly impair blood flow in several organs, including decreased cerebral blood flow. Transient ischemic infarcts and cerebral infarcts are frequent complications in MPNs due to occlusion of cerebral arteries. Furthermore, obstructions in small vessels might impact neuronal function and elicit acute neurodegeneration even in the absence of symptoms. Importantly, cerebral microinfarcts have been shown to be associated with a more abrupt decline in cognitive function and a higher risk of the development of dementia [49]. In this context, it is important to note that cognitive dysfunction has been demonstrated in patients with ET and PV in the absence of large vessel stroke. In such patients, a dysfunctional microcirculation might account for the neurological symptoms.

Recently, vasculature structure and cerebral blood flow have been investigated in MPN mouse models (JAK2V617F transgenic mice with PV, ET, or a mixed MPN phenotype) [43] aimed to describe the effects of excessive blood cells on cerebral microcirculation in ET and PV. A dramatic increase in the fraction of capillaries with stalled blood flow was recorded in MPN mice as compared with control mice [43].

As addressed above, RBCs from PV patients have been shown to have increased adhesion to endothelial cells. High hematocrit values also give rise to abnormally high shear stress on the vessel wall, which may not only facilitate endothelial dysfunction but also activation of leukocytes and platelets in patients with PV. Of note, both leukocyte and platelet activation are typically recorded in patients with PV, altogether facilitating increased adhesion of leukocytes and platelets in the microvasculature [8].

The findings in the MPN mouse models of abnormal stalling of capillaries due to high hematocrit, leukocyte plugs, and platelet aggregates support the clinical observations of cerebral microinfarction in a high proportion of MPN patients—also years before MPN-diagnosis [1, 2].

Indeed, having a large fraction of capillaries stalled may cause chronic brain hypoperfusion, contributing to increase the prevalence of cerebral thrombotic complications in patients with MPNs [8] but most likely also in patients with AD. Thus, cerebral hypoperfusion and microinfarcts are closely linked to cognitive decline in AD development, and silent brain infarcts have been found to double the risk of developing dementia [49]. Patients with silent brain infarcts suffer a broad spectrum of neurological symptoms, including memory deficits, cognitive and behavioral changes with attentional and executive impairments as well as depression [49, 50]—a CNS-symptom burden which by clinical experience is also prevalent in elderly patients with MPNs.

With reference to a reduced cerebral blood flow in patients with MPNs and in MPN mouse models, it is highly intriguing that a most recent novel mouse model study has substantiated that reduced cerebral blood plays a central role in the AD development [44]. This study demonstrated that neutrophils adhere to the walls of capillaries in the cerebral cortex, thereby blocking local blood flow. Importantly, it was also shown that this blockage is the first manifestation of the disease and actually precedes amyloid deposits. Cerebral blood flow was immediately restored after the administration of antibody blocking neutrophil adherence to endothelium in concert with a rapid improvement in the short-term memory tasks in the two murine models. This study further puts in perspective the importance of neutrophils in the development of AD [51] and thereby also the urgent need of exploring MPNs as “A Human Neuroinflammation Model” and the potential role of mutated blood cells giving rise to erythrocytosis with raised blood viscosity, leukocytosis with activated neutrophils and monocytes, and thrombocytosis with activated thrombocytes in AD development (Fig. 4).

Inflammatory cytokines are elevated and upregulated in patients with MPNs and Alzheimer’s disease

Several studies have investigated the dysregulation of cytokine levels in patients with MPNs [3,4,5,6,7], demonstrating that circulating inflammatory cytokines are elevated with an increasingly dysregulated cytokine profile in the biological continuum from ET and PV to MF as evidenced by whole blood gene expression profiling studies (Figs. 1 and 3) [3,4,5,6,7].

Accordingly, as previously noted, chronic inflammation is today widely recognized as a driver of clonal evolution and significantly contributes to the MPN-symptom burden, including the massive cardiovascular disease burden but also the CNS-related symptoms which may be attributed to “MPN-induced neuroinflammation” (Figs. 1, 2, and 3).

As alluded to above, several lines of evidence support the notion that neuroinflammation may be part of the MPN-associated CNS-symptom complex, including fatigue, anxiety, cognitive dysfunction, and memory loss. Indeed, these symptoms may be the first signals of incipient development of AD in the patient with MPN, but no studies have systematically addressed this highly important issue. Interestingly, patients with AD exhibit elevated peripheral inflammatory cytokine levels very similar to those recorded in patients with MPNs, including elevated C-reactive protein, interleukin-1β (IL-1β), IL-2, IL-6,IL-8, IL-12, IL-18, soluble tumor necrosis factor receptor1 (sTNFR1), soluble tumor necrosis factor receptor2 (sTNFR2), monocyte chemotactic protein-1 (MCP-1), MCP-3, interferon-γ-inducible protein 10, and soluble CD40 ligand. Several of these inflammatory markers have also been found to be elevated in cerebrospinal fluid of patients with AD, including in addition elevated levels of IL-10, transforming growth factor-beta1 (TGFB1), YKL-40, and soluble triggering receptor expressed on myeloid cells2 (TREM2) [52, 53].

Smoking is a risk factor for the development of MPNs and Alzheimer’s disease

Recently, smoking was suggested as a contributing factor for development of MPNs, taking into account that in both smokers and in patients with MPNs the JAK-STAT and NF-kappaB signaling pathways are activated and both share additionally elevated levels of several proinflammatory cytokines, in vivo activation of leukocytes and platelets, endothelial dysfunction, and increased systemic oxidative stress [54]. Later, several studies have confirmed the association between smoking and MPNs [55].

Several studies have shown that smoking is also a risk factor for development of AD [56], being likely explained by all the factors addressed above for smokers and patients with MPNs, including raised levels of proinflammatory cytokines, in vivo activation of leukocytes and platelets, endothelial dysfunction, and increased systemic oxidative stress which all also are operative in the development of AD (Figs. 1 and 3, Table 1).

Disintegration of the blood-brain barrier (BBB) and brain vessel angiopathy in Alzheimer’s disease—a consequence of in vivo platelet activation with release of excessive amounts of Aβ and angiogenic growth factors in brain vessels?

As previously addressed, platelet activation may be of particular importance in the context of an association between MPNs and AD. Thus, in patients with MPNs, platelets are constitutively activated, thereby releasing vast amounts of granule constituents, including Aβ and angiogenic growth factors, giving rise to excessive overload of Aβ in the vascular system. In the brain, the excessive release and deposition of Aβ from hyperactive platelets at the endothelium together with release of angiogenic growth factors (e.g., VEGF) likely may disrupt and compromise the blood-brain barrier (BBB) and significantly contribute to the development of cerebral amyloid angiopathy (CAA) as well, thereby adding to the severity of AD, since CAA induces degeneration or destruction of the vessel wall and impairs cerebral blood flow [57].

Since platelets are also activated by Aβ, a vicious self-perpetuating cycle is prone to be established in the cerebral microcirculation with further Aβ release and consequently Aβ-mediated platelet activation and enhanced platelet adhesion on subendothelial matrix proteins. Ultimately, continued recruitment of activated platelets to Aβ deposits may lead to complete blood vessel occlusion. The above scenario has been comprehensively described recently and might be even more exaggerated in patients with MPNs due to high numbers of circulating hyperactivated platelets—a continuous supply of fuel to the vicious circle as described above and accordingly supporting MPNs as “A Human Neuroinflammation for Development of Alzheimer’s Disease.”

Elevated oxidative stress in patients with MPNs and Alzheimer’s disease

Inflammation generates reactive oxygen species (ROS), and recently the JAK2V617F mutation per se has been shown to induce the accumulation of ROS in the hematopoietic stem cell compartment. Using whole blood transcriptional profiling, a massive deregulation of genes involved in oxidative stress and anti-oxidative stress mechanisms has been reported in patients with MPNs with a significant upregulation of several oxidative stress genes in concert with downregulation of important antioxidative defence genes [58]. Oxidative stress is associated with overproduction of several proinflammatory cytokines (e.g., TNF-alpha, IL-1beta, IL-2, IL-6, IL-8, IL-12) which, in turn, can cause oxidative stress in hematopoietic cells in bone marrow and peripheral blood but in other organs as well including the CNS. Recently, oxidative stress has been highlighted as a most important mechanism in the pathogenesis of AD [59].

Age-related macular degeneration (AMD) is prevalent in MPNs and in Alzheimer’s disease (AD). Is amyloid beta release from activated platelets a contributory mechanism for AMD and AD development in MPNs?

Recently, we have shown that age-related macular degeneration (AMD) is far more common in patients with MPNs than in the background population. Since chronic inflammation is considered of utmost importance for the development of both AMD, AD, and MPNs and complement activation is also involved in AMD and AD pathogenesis, it is intriguing to speculate if chronic inflammation and complement activation are common pathways which associate these diseases. Highly interesting, in vitro stimulation of retinal pigment cells with Aβ1-40, abundant in platelets, and a constituent of drusen has been shown to promote changes in gene expression and cellular pathways [60] which are implicated in the pathogenesis of both AMD, AD, and MPNs, including oxidative stress, inflammation, and angiogenesis. Whether the tight association between AMD and MPNs might also be explained by excessive release of Aβ from circulating hyperactive platelets and if a similar mechanism is operative in the Alzheimer brain as well remains elusive and a topic for future research.

Down’s syndrome—a model disease for the increased risk of Alzheimer’s disease in individuals with a concurrent risk of myeloid blood cancer

Down’s syndrome (DS) is caused by an extra copy of chromosome 21 which is the most common genetic risk factor for childhood leukemia. Thus, the incidence of acute megakaryoblastic leukemia (AMKL) in children with DS is approximately 500 times higher than that in the general population. A transient myeloproliferative disorder (TMD), which resolves spontaneously, develops in 10% of DS babies, of whom about 20% develop AMKL after several years. Accordingly, during the first years of life, some patients with DS display elevated hematocrit and platelet counts.

Taking into account the abnormal hematopoietic homeostasis in DS patients with a propensity to develop a TMD in childhood and in a subset of these patients after several years AMKL, it is intriguing to speculate if circulating erythrocytes, leukocytes, and platelets—both in early childhood and later—may actually be abnormal, implying an enhanced adherence of leukocytes and platelets to each other and the endothelium in the microcirculation, an enhanced release of intracellular constituents, including Aβ with ultimate deposition in the cerebral microcirculation and cerebral hypoperfusion due to blocking of cerebral capillaries with neutrophils and platelets as previously alluded to. Indeed, a latency period of 10–20 years before AD development in DS patients is compatible with the earlier development of AD in DS—often before the 40th year of life in several patients—and the fact that AD is preceded by a period of 10–20 years, in which patients may be virtually asymptomatic or with only minor cognitive and memory deficits.

Patients with DS exhibit biochemical features of chronic inflammation as evidenced by elevated circulating levels of several inflammatory cytokines and oxidative stress markers. Highly intriguing, a recent study has demonstrated that trisomy 21 causes consistent global changes in the circulating proteome compatible with chronic autoinflammation [61].

Altogether DS is the class type of the consequences of disordered hematopoiesis predisposing to the development of AD. In this context, it is important to note that the abnormal hematopoiesis involves the myeloid cell lineage—and in particular—the megakaryocytic cell lineage with increased production of platelets and release of a huge amount of platelet constituents, which together with blocking of cerebral capillaries with activated leukocytes and platelets may lead to chronic cerebral hypoperfusion—one of the hallmarks of AD. As such, the link between DS, a TMD, AMKL, and AD only adds fuel to the hypothesis and the concept that MPNs—acquired stem cell neoplasms with involvement of the megakaryocyte cell lineage in all MPN-subtypes (ET, PV, and MF)—are “A Human Neuroinflammation Model” for AD development.


Alzheimer’s disease is the most common cause of dementia, being characterized by a decline in cognitive function and neuronal loss [26, 27]. The disease is foreseen to become increasingly prevalent in concert with rising life expectancy. Given the socio-economic burden of AD, the identification of novel mechanisms and predisposing factors for AD pathogenesis and development, as well as novel therapeutic targets [62] is urgently needed.

Herein, we have provided evidence that MPNs are diseases, which constitute “A Human Neuroinflammation Model” and accordingly may be associated with an increased risk of developing AD similar to other chronic inflammatory diseases, such as type II DM. Several lines of evidence support the contention of an association between MPNs and AD. First, the MPNs are associated with mutations in blood cells that give rise to elevated cell counts—red blood cells, white blood cells, and platelets [1], which are associated with impaired cerebral blood flow [23, 46], stalled capillary blood flow in mouse models of ET and PV [43], ischemia, and infarction, including silent microinfarctions in the cerebral microcirculation. Second, the circulating blood cells in MPN patients are constitutively activated with enhanced adherence to each other and the inflamed endothelium [8]. Third, the MPNs are associated with a sustained chronic inflammatory and oxidative stress state, which ultimately give rise to organ dysfunction and organ failure [3,4,5,6,7]. Although platelet activation and elevated levels of inflammatory cytokines, reflecting a chronic inflammatory state are common for both MPNs and AD, neither platelet activation per se nor chronic inflammation per se need to be causally involved in AD pathogenesis, since these conditions are recorded in several other diseases. However, given AD is so common and age-related it is indeed intriguing to consider a causality between platelet activation, chronic inflammation, and AD, since they are all tightly associated with aging (inflammaging/immunoaging). Fourth, a most recent study has unraveled sticking of neutrophils in cerebral capillaries—“stalling” of neutrophils—as one of the main cellular mechanisms, accounting for reduced cerebral blood flow in AD models [44]. As addressed above, similar stalling has been shown in cerebral capillaries of MPN mouse models [43]. Fifth, the link between DS, disordered congenital hematopoiesis, involving the myeloid cell lineage and early development of AD only adds further evidence to the concept that MPNs may be “A Human Neuroinflammation Model” for AD development.

The perspectives of an association between MPNs and AD are several. First, the hypothesis calls for MPN-mutation screening studies among patients with AD and in patient populations which we know have an increased risk of AD as well. Second, considering that treatment with interferon-alpha2 (IFN) normalizes elevated blood cell counts within weeks in the large majority of patients with early stage MPNs (ET, PV, and hyperproliferative myelofibrosis) [63] and interferon-beta most recently has shown potent anti-inflammatory activity in concert with improvement in cognitive function in AD patients [64] and in a rat model [65], studies of the safety and efficacy of interferon-alpha or beta in a larger series of AD patients, preferentially those with early stage disease, might be timely and relevant taking into account that no agents so far have been able to revert disease activity in this devastating disease. Of note, IFN treatment may also impact key factors of utmost pathogenetic importance for AD development, including downregulation of upregulated oxidative stress genes and upregulation of downregulated antioxidative defence genes [66]. Furthermore, IFN also significantly downregulates several upregulated thromboinflammatory genes, not least PADI4, which enhances thrombosis development [67]. Combination therapy with IFN and ruxolitinib—a highly potent anti-inflammatory agent that induces a rapid decline in elevated inflammatory cytokines in concert with alleviation of constitutional symptoms—might also be an attractive approach, since this drug combination has displayed synergistic effects in MPN patients (Fig. 2) [68]. In patients with early stage AD and no MPN disease, treatment with the cytoreductive agent hydroxyurea might be highly interesting, since it has been used successfully for decades in the treatment of patients with sickle cell anemia to reduce the serious complications to this disease, including infarctions in several organs owing to protrombogenic changes in blood cells—very similar to those encountered in patients with MPNs, in whom hydroxyurea worldwide is the most used agent to prohibit thrombotic events. Adding to this, hydroxyurea is not expensive and without safety concerns in patients not suffering a malignant stem cell disease (concern in regard to its leukemogenic potential in patients with MPNs and therefore not used in younger patients).


In conclusion, based upon a review of shared mechanisms for development of the chronic MPN blood cancers and Alzheimer’s disease and for reduction in cerebral blood flow, including chronic inflammation, involvement of activated myeloid blood cells, and capillary stalling with plugging of blood cells in the cerebral microcirculation, we believe that the hypothesis on MPNs as a “Human Neuroinflammation Model” for AD is worthy to pursue in the future by experimental studies in JAK2V617F knock-in mice together with mutation screening of AD patients and patients at high risk of housing MPN-mutations and not least epidemiological registry studies. Indeed, the most recent findings of a frequency of the JAK2V617F mutation in stroke patients of 8.3% [69] and in the background population of 3%, implying 10,000 undiagnosed MPNs in Denmark [11] only underscore and put in perspective the urgent need of such mutation screening studies in patients with AD as well. If our hypothesis is supported by results from the above studies, a novel therapeutic approach deserves to be tested in clinical trials addressing the safety and efficacy of monotherapy with IFN or in combination with ruxolitinib in AD. Such a combination therapy is even more timely in the perspective of a revival of the role of blood cells—leukocytes and platelets—in AD pathogenesis and the role of inflammasomes in neuroimmune and neurodegenerative diseases, targeting leukocytes and platelets potently by IFN and the inflammasome by potent anti-inflammatory JAK1-2 inhibition—ruxolitinib—or monoclonal antibodies targeting IL-1beta or IL-6 [70]. By targeting key drivers and the suggested roots of AD development - circulating blood cells - aiming to normalize leukocyte and platelet counts either reactive to chronic inflammatory diseases or clonal (MPNs)—by monotherapies (interferon or hydroxyurea) or in combination with, e.g., ruxolitinib (Fig. 2), such efforts seem more rational than trials, which target single components in AD development, e.g., antibodies targeting beta amyloid or chemokine receptors on leukocytes and platelets [62].

Availability of data and materials

Not applicable



Amyloid β-peptide


Alzheimer’s disease


Age-related macular degeneration


Acute megakaryoblastic leukemia


Amyloid precursor protein


Blood-brain barrier


Cerebral amyloid angiopathy




Central nervous system


Diabetes mellitus


Down’s syndrome


Essential thrombocythemia


Inflammatory bowel disease


Interferon-alpha2, interferon-beta


Janus kinase 2


Janus kinase-signal transducer and transcription




Myeloproliferative leukemia virus


Myeloproliferative neoplasms


Neutrophil extracellular trap


NET formation


Polycythemia vera


Red blood cell


Red blood cells


Reactive oxygen species


Transient myeloproliferative disorder


Vascular endothelial growth factor


  1. 1.

    Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376:2168–81.

    CAS  PubMed  Google Scholar 

  2. 2.

    Enblom A, Lindskog E, Hasselbalch H, et al. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. 2015;26:344–7.

    PubMed  Google Scholar 

  3. 3.

    Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–25.

    CAS  PubMed  Google Scholar 

  4. 4.

    Hasselbalch HC, Bjørn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015:1024765.

    Google Scholar 

  5. 5.

    Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;37:214–20.

    CAS  PubMed  Google Scholar 

  6. 6.

    Koschmieder S, Mughal TI, Hasselbalch HC, et al. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;30:1018–24.

    CAS  PubMed  Google Scholar 

  7. 7.

    Craver BMBBM, El Alaoui K, Scherber RM, et al. The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers (Basel). 2018;10:1–18.

    Google Scholar 

  8. 8.

    Barbui T, Finazzi G, Falanga A, et al. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176–84.

    CAS  PubMed  Google Scholar 

  9. 9.

    Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment? Leuk Res. 2009;33:11–8.

    CAS  PubMed  Google Scholar 

  10. 10.

    Ehlers S, Kaufmann SHE. Infection, inflammation, and chronic diseases: consequences of a modern lifestyle. Trends Immunol. 2010;31:184–90.

    CAS  PubMed  Google Scholar 

  11. 11.

    Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019;134(5):469–79.

    CAS  PubMed  Google Scholar 

  12. 12.

    Castello MA, Soriano S. On the origin of Alzheimer’s disease. Trials and tribulations of the amyloid hypothesis. Ageing Res Rev. 2014;13:10–2.

    CAS  PubMed  Google Scholar 

  13. 13.

    Karran E, De Strooper B. The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem. 2016;139:237–52.

    CAS  PubMed  Google Scholar 

  14. 14.

    Tse KH, Herrup K. Re-imagining Alzheimer’s disease – the diminishing importance of amyloid and a glimpse of what lies ahead. J Neurochem. 2017;143:432–44.

    CAS  PubMed  Google Scholar 

  15. 15.

    Behl C, Ziegler C. Beyond amyloid – widening the view on Alzheimer’s disease. J Neurochem. 2017;143:394–5.

    CAS  PubMed  Google Scholar 

  16. 16.

    Franceschi C, Campisi J. Chronic inflammation (Inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69:S4–9.

    PubMed  Google Scholar 

  17. 17.

    Pawelec G, Goldeck D, Derhovanessian E. Inflammation, ageing and chronic disease. Curr Opin Immunol. 2014;29:23–8.

    CAS  PubMed  Google Scholar 

  18. 18.

    Dutta P, Nahrendorf M. Regulation and consequences of monocytosis. Immunol Rev. 2014;262:167–78.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Nahrendorf M. Myeloid cell contributions to cardiovascular health and disease. Nat Med. 2018;24:711–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.

    CAS  Google Scholar 

  21. 21.

    Rockey DC, Bell PD, Hill JA. Fibrosis — a common pathway to organ injury and failure. N Engl J Med. 2015;372:1138–49.

    CAS  PubMed  Google Scholar 

  22. 22.

    Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.

    CAS  PubMed  Google Scholar 

  23. 23.

    Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous hæmatocrit in primary proliferative polycythaemia. Lancet. 1978;312:1219–22.

    Google Scholar 

  24. 24.

    Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015;90:864–70.

    PubMed  Google Scholar 

  25. 25.

    Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167.

    PubMed  PubMed Central  Google Scholar 

  26. 26.

    Cummings JL. Alzheimer’s disease. N ENGL J MED. 2004;351:56–67.

    CAS  PubMed  Google Scholar 

  27. 27.

    Querfurth HW, Laferla FM. Alzheimer’s disease. N ENGL J MED. 2010;362:329–44.

    CAS  PubMed  Google Scholar 

  28. 28.

    Di Luca M, Colciaghi F, Pastorino L, Borroni B, Padovani A, Cattabeni F. Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease: the case of amyloid precursor protein. Eur J Pharmacol. 2000;405:277–83.

    PubMed  Google Scholar 

  29. 29.

    Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.

    PubMed  Google Scholar 

  30. 30.

    Hardy J, Higgins G. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5.

    CAS  Google Scholar 

  31. 31.

    Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Bush AI, Martins R, Rumble B, et al. The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem. 1990;265(26):15977–83.

    CAS  PubMed  Google Scholar 

  33. 33.

    Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid β-peptide in human blood. Biochem. Biophys. Res. Commun. 1995;213:96–103.

    CAS  PubMed  Google Scholar 

  34. 34.

    Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid B-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med. 1996;2:864–70.

    CAS  PubMed  Google Scholar 

  35. 35.

    Davies TA, Long HJ, Sgro K, et al. Activated Alzheimer disease platelets retain more beta amyloid precursor protein. Neurobiol Aging. 1997;18:147–53.

    CAS  PubMed  Google Scholar 

  36. 36.

    Canobbio I, Visconte C, Oliviero B, et al. Increased platelet adhesion and thrombus formation in a mouse model of Alzheimer’s disease. Cell Signal. 2016;28:1863–71.

    CAS  PubMed  Google Scholar 

  37. 37.

    Kucheryavykh LY, Dávila-rodríguez J, Rivera-aponte DE, et al. Platelets are responsible for the accumulation of β-amyloid in blood clots inside and around blood vessels in mouse brain after after thrombosis. Brain Res Bull. 2017;128:98–105.

    CAS  PubMed  Google Scholar 

  38. 38.

    Kövari E, Herrmann FR, Hof PR, Bouras C. The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer’s disease. Neuropathol Appl Neurobiol. 2013;39:498–509.

    PubMed  PubMed Central  Google Scholar 

  39. 39.

    Horstman LL, Jy W, Ahn YS, et al. Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation. 2010;7:1–22.

    Google Scholar 

  40. 40.

    Gowert NS, Donner L, Chatterjee M, et al. Blood platelets in the progression of Alzheimer’s disease. PLoS One. 2014;9.

  41. 41.

    Shad KF, Aghazadeh Y, Ahmad S, Kress B. Peripheral markers of Alzheimer’s disease: surveillance of white blood cells. Synapse. 2013;67:541–3.

    CAS  PubMed  Google Scholar 

  42. 42.

    Pietronigro EC, Della Bianca V, Zenaro E, Constantin G. NETosis in Alzheimer’s disease. Front Immunol. 2017;8:1–12.

    Google Scholar 

  43. 43.

    Santisakultarm TP, Paduano CQ, Stokol T, et al. Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. 2014;12:2120–30.

    CAS  PubMed  Google Scholar 

  44. 44.

    Cruz Hernandez JC, Bracko O, Kersbergen CJ, et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models. Nat Neurosci. 2019;22:413–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Fulop T, Lacombe G, Cunnane S, et al. Elusive Alzheimer’s disease: can immune signatures help our understanding of this challenging disease? Part 2: new immune paradigm. Discov Med. 2013;15(80):33–42.

    PubMed  Google Scholar 

  46. 46.

    Thomas DJ, Marshall J, Russell RWR, et al. Effect of haematocrit on cerebral blood-flow in man. Lancet. 1977;2:941–3.

    CAS  PubMed  Google Scholar 

  47. 47.

    Jayakumar R, Kusiak JW, Chrest FJ, et al. Red cell perturbations by amyloid beta-protein. Biochim Biophys Acta. 1622;2003:20–8.

    Google Scholar 

  48. 48.

    Mohanty JG, Eckley DM, Williamson JD, Launer LJ, Rifkind JM. Do red blood cell-beta-amyloid interactions alter oxygen delivery in Alzheimer’s disease? Adv Exp Med Biol. 2008;614:29–35.

    CAS  PubMed  Google Scholar 

  49. 49.

    Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMBB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215–22.

    PubMed  Google Scholar 

  50. 50.

    Kovari E, Gold G, Herrmann FR, et al. Cortical microinfarcts and demyelination affect cognition in cases at high risk for dementia. Neurology. 2007;68:927–31.

    CAS  PubMed  Google Scholar 

  51. 51.

    Zenaro E, Pietronigro E, Della Bianca V, et al. Neutrophils promote Alzheimer’s disease-like pathology and cognitive decline via LFA-1 integrin. Nat Med. 2015;21:880–6.

    CAS  PubMed  Google Scholar 

  52. 52.

    Su C, Zhao K, Xia H, Xu Y. Peripheral inflammatory biomarkers in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. Psychogeriatrics. 2019;19:300–9.

    PubMed  Google Scholar 

  53. 53.

    Shen X-N, Niu L-D, Wang Y-J, et al. Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry. 2019;90:590–8.

    PubMed  Google Scholar 

  54. 54.

    Hasselbalch HC. Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leuk Res. 2015;39:1137–45.

    CAS  Google Scholar 

  55. 55.

    Pedersen KM, Bak M, Sorensen AL, et al. Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study. Cancer Med. 2018;7:5796–802.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Durazzo TC, Mattsson N, Weiner MW. Smoking and increased Alzheimer’s disease risk: a review of potential mechanisms. Alzheimer’s Dement. 2014;10:S122–45.

    Google Scholar 

  57. 57.

    Thal DR, Griffin WST, de Vos RAI, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease. Acta Neuropathol. 2008;115:599–609.

    CAS  PubMed  Google Scholar 

  58. 58.

    Hasselbalch HC, Thomassen M, Riley CH, et al. Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. PLoS One. 2014;9:1–9.

    Google Scholar 

  59. 59.

    Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid Med Cell Longev. 2013;2013:316523.

    PubMed  PubMed Central  Google Scholar 

  60. 60.

    Kurji KH, Cui JZ, Lin T, et al. Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2010;51:1151–63.

    PubMed  Google Scholar 

  61. 61.

    Sullivan KD, Evans D, Pandey A, et al. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Sci Rep. 2017;7:1–11.

    Google Scholar 

  62. 62.

    Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2018. Alzheimer’s Dement Transl Res Clin Interv. 2018;4:195–214.

    Google Scholar 

  63. 63.

    Hasselbalch HC, Holmstrom MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41:5–19.

    CAS  PubMed  Google Scholar 

  64. 64.

    Grimaldi LME, Zappala G, Iemolo F, et al. A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects. J Neuroinflammation. 2014;11:30.

    PubMed  PubMed Central  Google Scholar 

  65. 65.

    Mudò G, Frinchi M, Nuzzo D, et al. Anti-inflammatory and cognitive effects of interferon-β1a (IFNβ1a) in a rat model of Alzheimer’s disease. J Neuroinflammation. 2019;16:1–16.

    Google Scholar 

  66. 66.

    Skov V, Riley C, Thomassen M, et al. Interferon-alpha2 significantly downregulates upregulated oxidative stress genes and upregulates downregulated anti-oxidative defence genes in patients with polycythemia vera and associated neoplasms. Blood. 2018;132(Supplement 1):4326.

    Google Scholar 

  67. 67.

    Skov V, Riley C, Thomassen M, et al. Significantly upregulated thrombo-inflammatory genes are normoregulated or significantly downregulated during treatment with interferon-alpha2 in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Blood. 2019;134(Supplement_1):2978.

    Google Scholar 

  68. 68.

    Mikkelsen SU, Kjaer L, Bjørn ME, et al. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Med. 2018;7:3571–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Chen CC, Hsu CC, Huang CE, et al. Enhanced risk for specific somatic myeloproliferative neoplastic mutations in patients with stroke. Curr Neurovasc Res. 2017;14(3):222–31.

    CAS  PubMed  Google Scholar 

  70. 70.

    Lang Y, Chu F, Shen D, et al. Role of inflammasomes in neuroimmune and neurodegenerative diseases: a systematic review. Mediators Inflamm. 2018;2018:1–11.

    Google Scholar 

Download references


Not applicable


Not applicable

Author information




HCH wrote the draft manuscript, designed the figures and table; all co-authors (TCW, TLS, VS, CE, LK) contributed substantially with revision and improvement of the manuscript. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Hans C. Hasselbalch.

Ethics declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

All authors have given consent for publication of the manuscript.

Competing interests

Hans Carl Hasselbalch has received Novartis research grant and is a member of the advisory board for AOP Orphan.

The other co-authors declare no competing financial interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hasselbalch, H.C., Skov, V., Kjær, L. et al. Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives. J Neuroinflammation 17, 248 (2020).

Download citation


  • Alzheimer’s disease
  • Myeloproliferative neoplasms
  • Essential thrombocythemia
  • Polycythemia vera
  • Myelofibrosis
  • Blood cancer mutations
  • JAK2V617F
  • TET2
  • Chronic inflammation
  • Dementia
  • Thrombosis
  • Capillary stalling
  • Cerebral hypoperfusion
  • JAK1/2-inhibitor
  • Interferon-alpha2
  • Interferon-beta
  • Hydroxyurea